Phase II Trial of Allovectin-7® for Head and Neck Cancer

Carcinoma of the Head and Neck, Head and Neck Cancer, Head and Neck Neoplasms, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Cancer, Carcinoma, Neoplasm, Head cancer, Neck cancer, Tongue cancer, Lip cancer, Oral Cavity, Oropharynx, Pharynx, Larynx, Squamous Cell, Salivary Glands, Tumor, Lesion, Cancer treatment, Clinical trial, Allovectin-7®, Otorhinolaryngologic Neoplasm, Otolaryngologic Cancer, Gene therapy, Immunotherapy, Cancer research, Cancer vaccine, Cancer cells

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Treatment - If you take part in this trial you will be treated for about four weeks. You will receive an injection of Allovectin-7® by needle, directly into your tumor. This will be repeated 14 days later. The injections may be given in a doctor's office. A week later, you will undergo surgery to remove the tumor. Your tumor will be measured before Allovectin-7® treatment and before surgery to see if Allovectin-7® was effective in shrinking it. This will be done by general physical exams and scans (such as X-ray scans). There will also be tests on the removed tumor to see if Allovectin-7® helped to boost the immune system to attack the cancer.

No related papers found yet.

United States